Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lifevantage Corporation (LFVN : NSDQ)

• Company Description    Lifevantage Corporation is a health and nutrition company. The company is the maker of Protandim(R), the Nrf2 Synergizer(R) patented dietary supplement, the TrueScience(TM) Anti-Aging Skin Care Regimen, Canine Health and the AXIO(TM) energy product line. Lifevantage Corporation is headquartered in Salt Lake City, Utah. Number of Employees: 238

• Price / Volume Information    Yesterday's Closing Price: $5.34 Daily Weekly Monthly 20 Day Moving Average: 277,878 shares Shares Outstanding: 12.62 (millions) Market Capitalization: $67.37 (millions) Beta: 0.52 52 Week High: $15.00 52 Week Low: $3.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 28.67% 18.55% 12 Week 6.16% -1.91% Year To Date -13.31% -19.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 N. TRIUMPH BLVD SUITE 700 - LEHI,UT 84043 USA ph: 801-432-9000 fax: 801-880-0699 reed.anderson@icrinc.com http://www.lifevantage.com

• General Corporate Information    Officers Steven R. Fife - Chief Executive Officer; President Raymond B. Greer - Chairman Rajendran Anbalagan - Director Michael A. Beindorff - Director Dayton Judd - Director Peer Information Lifevantage Corporation (ITRJ) Lifevantage Corporation (BRLI.) Lifevantage Corporation (GOGY) Lifevantage Corporation (PSTX.) Lifevantage Corporation (ELGXQ) Lifevantage Corporation (CAH) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED/DENTAL-SUPP Sector: Medical CUSIP: 53222K205 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/03/26 Share - Related Items Shares Outstanding: 12.62 Most Recent Split Date: 10.00 (0.14:1) Beta: 0.52 Market Capitalization: $67.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 3.37% Current Fiscal Quarter EPS Consensus Estimate: $0.17 Indicated Annual Dividend: $0.18 Current Fiscal Year EPS Consensus Estimate: $0.60 Payout Ratio: 0.29 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: -0.05 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 03/02/2026 - $0.05 Next EPS Report Date: 09/03/26

• Fundamental Ratios P/E Current FY Estimate: 8.90 Trailing 12 Months: 8.61 PEG Ratio: - Price Ratios Price/Book: 2.05 Price/Cash Flow: 4.86 Price / Sales: 0.34 EPS Growth vs. Year Ago Period: -53.85% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: -25.20% vs. Previous Quarter: -10.66% ROE 03/31/26 - 23.89 12/31/25 - 29.59 09/30/25 - 33.52 ROA 03/31/26 - 12.47 12/31/25 - 14.67 09/30/25 - 15.81 Current Ratio 03/31/26 - 1.96 12/31/25 - 2.03 09/30/25 - 2.39 Quick Ratio 03/31/26 - 1.04 12/31/25 - 1.03 09/30/25 - 1.30 Operating Margin 03/31/26 - 4.10 12/31/25 - 4.75 09/30/25 - 4.82 Net Margin 03/31/26 - 2.94 12/31/25 - 3.74 09/30/25 - 4.43 Pre-Tax Margin 03/31/26 - 3.46 12/31/25 - 4.42 09/30/25 - 5.20 Book Value 03/31/26 - 2.60 12/31/25 - 2.60 09/30/25 - 2.61 Inventory Turnover 03/31/26 - 2.17 12/31/25 - 2.17 09/30/25 - 2.23 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©